Investigation Into Liquidia Technologies for Shareholder Rights
Bronstein, Gewirtz & Grossman, LLC is launching an investigation into potential claims related to Liquidia Technologies, Inc. (NASDAQ: LQDA). This inquiry aims to uncover any misconduct that may have impacted the company’s shareholders and their investments.
Understanding the Allegations
Recently, Liquidia announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for its inhalation product YUTREPIA™, designed to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
However, this approval is dependent on the expiration of regulatory exclusivity held by a competing product. Following this announcement, Liquidia's stock saw a significant drop, falling by $4.32 per share, which represents a 30.62% decrease, closing at $9.79.
What Should Investors Do?
Investors who have purchased Liquidia securities or possess pertinent information regarding this investigation are urged to take action. They can gather more details and participate in the investigation by contacting Bronstein, Gewirtz & Grossman, LLC.
Why Choose Bronstein, Gewirtz & Grossman, LLC?
This firm is nationally recognized in the legal field, specializing in representing investors in securities fraud class actions and shareholder derivative suits. With a strong track record, they have successfully recovered hundreds of millions of dollars for investors across the nation.
Client-Dedicated Approach
Bronstein, Gewirtz & Grossman operates on a contingency fee basis, meaning that clients only incur legal fees if the firm achieves a successful outcome on their behalf. This approach significantly reduces the financial burden for shareholders pursuing claims against potential injustices.
Contact Information
For any inquiries or to share information related to the investigation, investors can reach out directly to the firm. Peretz Bronstein and Nathan Miller are available to assist clients and ensure that all concerns are effectively addressed. They can be contacted at 332-239-2660.
Frequently Asked Questions
What is the purpose of the investigation into Liquidia Technologies?
The investigation seeks to identify any misconduct that may have impacted shareholders and their investments in Liquidia Technologies.
How can I participate in the investigation?
Investors can join the investigation or provide information by reaching out to Bronstein, Gewirtz & Grossman, LLC.
What happened to Liquidia's stock price?
After the announcement of tentative FDA approval, Liquidia's stock price experienced a significant decline, resulting in a 30.62% drop.
What does Bronstein, Gewirtz & Grossman charge for their services?
The firm operates on a contingency fee basis, meaning they only charge clients if they win the case, which helps minimize upfront costs for investors.
Who should I contact for more information about the investigation?
For further inquiries regarding the investigation, you can contact Peretz Bronstein or Nathan Miller at Bronstein, Gewirtz & Grossman.
